| Japanese |
|---|
| Title | 131I摂取を認めずT3によるTSH抑制療法にて多発性肺転移巣の縮小を認めた分化型甲状腺癌の一例 |
|---|
| Subtitle | 症例報告 |
|---|
| Authors | 小須田茂*, 新井真二*, 法師人儀人*, 徳光英行*, 草野正一*, 門田俊夫** |
|---|
| Authors(kana) | |
|---|
| Organization | *防衛医科大学校放射線医学講座, **入間川病院外科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 34 |
|---|
| Number | 10 |
|---|
| Page | 925-931 |
|---|
| Year/Month | 1997/10 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 要旨 症例は甲状腺乳頭癌全摘術後の28歳女性で, 多発性肺転移巣が出現したため, 131Iによる治療目的にて当院放射線科を受診した. 131Iによる残存甲状腺のablationを施行後, トレーサ量による131I全身スキャンを行ったが, 肺転移巣に131Iの摂取を認めなかった. T4よりT3に変更して, 血中TSH0.1μU/ml以下になるよう抑制療法を続けたところ, T3服用開始後2か月で多発性肺転移巣は縮小傾向を示し, 8か月後では著明な肺転移巣縮小を認めた. 胸部X線上の縮小率は, 33-76%であった. CT上, 各転移巣で縮小率にバラツキがみられたが, 肺転移巣縮小は明らかであった. CT上新たな転移巣を示した病巣は認めなかった. 血中サイログロブリン値は80より25ng/mlに下降した. T3服用開始後4年6か月経過した現在, 病巣の進展を見ない. 分化型甲状腺癌に対するT3によるTSH抑制療法は予後を改善するかもしれない. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Differentiated thyroid carcinoma, Thyrotropin suppression, Pulmonary metastasis, Triiodothyronine. |
|---|
| English |
|---|
| Title | Successful TSH Suppression Therapy with Triiodothyronine in a Patient with Pulmonary Metastases from Differentiated Thyroid Carcinoma in the Absence of 131I Uptake |
|---|
| Subtitle | Case Reports |
|---|
| Authors | Shigeru KOSUDA*, Shinji ARAI*, Yoshito HOHSHITO*, Hideyuki TOKUMITSU*, Shoichi KUSANO*, Toshio KADOTA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, National Defense Medical College, **Department of Surgery, Irumagawa Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 34 |
|---|
| Number | 10 |
|---|
| Page | 925-931 |
|---|
| Year/Month | 1997/10 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | A 28-year-old woman was referred to us to undergo 131I therapy who had multiple pulmonary metastases from papillary thyroid carcinoma after total thyroidectomy. There was no increased accumulation of a tracer in the pulmonary metastatic foci on whole-body scanning using a 111 MBq diagnostic dose of 131I. However, the pulmonary metastases were gradually decreased in size, and then clearly reduced 8 months after the start of TSH suppression therapy, which was maintained by T3 instead of T4 to bring down the serum TSH level below 0.1μU/ml. Reduction rates of the foci were 33-76% on chest X-ray. The reduction was confirmed and no new lesions were found on the serial CT scans. Serum thyroglobulin level was lowered 80 to 25 ng/ml by this suppression therapy and progression of disease was not observed under a 54 months' T3 treatment. Thus, TSH suppression therapy might improve survival of patients with differentiated thyroid cancer. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Differentiated thyroid carcinoma, Thyrotropin suppression, Pulmonary metastasis, Triiodothyronine. |
|---|